Diversified Healthcare Trust (DHC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights positive financial performance with increased revenues, NOI, and occupancy across various segments. Despite temporary labor cost increases, the company maintains strong guidance and expects favorable transitions. The Q&A section reveals management's confidence in achieving targets and mitigating risks. The increase in SHOP NOI guidance and active disposition pipeline further support a positive outlook. However, the lack of specific details on potential revenue disruptions and disposition delays warrants caution. Overall, the sentiment leans towards positive due to strong financial metrics and optimistic guidance.
Key Financial Performance
Total Revenue $388.7 million, an increase of 4% year-over-year. The increase reflects continued momentum across operating segments and steady execution on initiatives to strengthen DHC's financial position.
Adjusted EBITDAre $62.9 million. No year-over-year change or reasons for change were mentioned.
Normalized FFO $9.7 million or $0.04 per share. No year-over-year change or reasons for change were mentioned.
SHOP Occupancy Increased 210 basis points year-over-year to 81.5%. The increase reflects the fourth consecutive quarter of occupancy growth.
RevPOR (Revenue Per Occupied Room) Rose 5.3% year-over-year. The increase is attributed to annual rate increases, gains in care level pricing, and reduced discounts and concessions at higher occupied communities.
ExpensePOR (Expense Per Occupied Room) Increased by 5.1% year-over-year. The increase is primarily driven by temporary labor cost increases associated with community transitions, wage adjustments, and filling of previously opened positions.
SHOP Revenues Increased 6.9% year-over-year. The increase is due to higher occupancy and RevPOR.
Consolidated SHOP NOI Increased 7.8% year-over-year to $29.6 million. The increase is attributed to higher occupancy and RevPOR, despite temporary labor cost increases.
Medical Office and Life Science Portfolio Occupancy Increased 370 basis points sequentially to 86.6%. The increase is primarily driven by asset sales of vacant or low occupancy properties and leasing during the quarter.
Same-Property Cash Basis NOI (Medical Office and Life Science Portfolio) Increased 1.6% year-over-year. Margins improved by 100 basis points to 58.9%. No specific reasons for the increase were mentioned.
Same-Property SHOP NOI Increased 6.6% year-over-year. The increase is due to improvements in occupancy and average monthly rate.
Same-Property SHOP Occupancy Increased 140 basis points year-over-year. The increase reflects positive momentum in occupancy.
Same-Property SHOP Average Monthly Rate Increased 5.3% year-over-year. The increase is attributed to pricing momentum.
Net Debt-to-Adjusted EBITDAre 10x, reflecting temporary compensation expense increases from the SHOP segment. Excluding $5.1 million of elevated compensation expenses, leverage would have been 9.3x, an improvement of 70 basis points.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Transition of AlerisLife-managed communities: DHC is transitioning 116 AlerisLife-managed communities to new operators, with 85 already transitioned. This is part of AlerisLife's wind-down strategy. The transition is expected to be completed by year-end 2025.
SHOP portfolio performance: SHOP occupancy increased 210 basis points year-over-year to 81.5%, marking the fourth consecutive quarter of growth. RevPOR rose 5.3%, and SHOP revenues increased by 6.9% year-over-year.
Medical Office and Life Science portfolio leasing: 86,000 square feet of leasing completed at weighted average rents 9% above prior rents. Consolidated occupancy increased 370 basis points to 86.6%.
Asset sales and proceeds: Year-to-date, DHC sold 44 properties for $396 million and has agreements to sell 38 more properties for $237 million. These sales will improve occupancy, margins, and cash flow.
Labor costs during transition: Temporary labor costs increased by $5.1 million due to the transition of AlerisLife communities, driven by operational support and employee overlap.
Capital investments: $43 million invested in Q3, including $35 million in SHOP communities and $7 million in Medical Office and Life Science portfolio. Incremental NOI of $2.8 million achieved from completed projects.
Debt refinancing and liquidity: DHC refinanced $1 billion for Vertex Pharmaceuticals' headquarters and issued $375 million in senior secured notes. The company plans to repay its 2026 bonds by year-end, leaving no maturities until 2028.
Geographic alignment strategy: Transitioning to a geographically aligned operating model with new 10-year operating agreements for SHOP communities, incorporating performance-based incentives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Elevated labor costs: The transition of 116 AlerisLife communities to new operators has led to elevated labor costs, including payroll allocation for property tours, community reviews, training, onboarding, and temporary employee overlap. This has resulted in an incremental cost of $5.1 million for the quarter.
Temporary decline in NOI: The transition of senior housing operating portfolio has caused a temporary decline in net operating income (NOI) due to increased labor costs and operational adjustments.
Debt leverage: Net debt-to-adjusted EBITDAre is currently high at 10x, reflecting elevated compensation expenses. Even excluding these expenses, leverage remains high at 9.3x, posing financial risk.
Asset sales dependency: The company is heavily reliant on asset sales to repay debt and improve liquidity. Delays or challenges in completing these sales could impact financial stability.
Occupancy and revenue risks: While SHOP occupancy and revenue have shown improvement, they remain below industry averages, and there is uncertainty about achieving consistent growth.
Transition execution risks: The transition of 116 communities to new operators involves operational complexities and risks, including potential disruptions in service quality and delays in achieving expected efficiencies.
Regulatory and compliance risks: The transition and new operating agreements may face regulatory scrutiny or compliance challenges, which could delay or complicate execution.
Interest rate and refinancing risks: The company has issued $375 million of 5-year secured bonds at a fixed coupon of 7.25%. Rising interest rates or unfavorable refinancing conditions could increase financial strain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
SHOP NOI guidance: Reaffirmed 2025 SHOP NOI guidance range of $132 million to $142 million.
Medical Office and Life Science portfolio: 1.5% of annualized revenue is scheduled to expire through year-end 2025, with 22,000 square feet expected to vacate. Active leasing pipeline totals 717,000 square feet, including 103,000 square feet of new absorption, with average lease terms of 7.6 years and GAAP rent spreads averaging more than 8%.
Capital markets and balance sheet initiatives: DHC plans to repay all amounts on January 2026 bonds as early as year-end, with no debt maturities until 2028. Asset sales of 38 properties for $237 million are expected to close by Q1 2026, reducing capital spending and improving cash flow.
SHOP segment performance: Expect improvements in adjusted EBITDAre with a full year 2025 range of $275 million to $285 million, trending towards positive cash flow as SHOP operations stabilize and leverage declines.
Transition of AlerisLife communities: All 116 communities are expected to transition to new operators by year-end 2025, with anticipated improvements in occupancy rates and NOI margins to align with industry averages.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What impact are you expecting from operator transition OpEx costs in 4Q '25, especially relative to 3Q?
A:Approximately $5.1 million of costs were incurred in 3Q due to transitions. For 4Q, the impact is expected to be around $1.5 million to $2 million. The overall NOI guidance remains unchanged at $132 million to $142 million for the year, supported by increases in occupancy and reductions in expenses, mainly utilities.
Q:Was the 10.1% margin ex the transition labor compensation expense a same-store number or for the consolidated portfolio?
A:It was a consolidated number.
Q:Were operator transition costs contemplated in the adjusted guidance provided earlier this year? Why was the transition from AlerisLife assets to third-party operators made now?
A:The guidance did not specifically quantify the interruption related to AlerisLife management contracts. The transition was driven by AlerisLife's strategic decision to meet business needs and improve performance. AlerisLife-managed communities outperformed others, and the transition aligns with a broader strategy to diversify operators and improve overall performance heading into 2026 and beyond.
Q:Are you still expecting occupancy to be in the 82% to 83% range by year-end?
A:Yes.
Q:Has there been any temporary disruption on the revenue side due to operator transitions?
A:It is difficult to quantify any top-line disruption from the transitions. However, top-line performance is trending favorably, and the impact has been more on the expense side. Most transitions will be completed by mid-November, which will reduce noise and allow focus on operations.
Q:Were there any other SHOP operating expense increases unrelated to transitions in the quarter?
A:The major headline was the $5.1 million in elevated compensation costs. Additionally, there was a $2.5 million sequential increase in utilities, which was expected and highlighted in the Q2 earnings call.
Q:Can you provide more color on the disposition activity pipeline? How close are these to closing, and what variables could cause delays?
A:A small portion of dispositions will close in Q1 2026, primarily on the SHOP side, involving 13 communities in a portfolio transaction. Over $200 million is expected to close in Q4, involving MOB and select SHOP assets. The risk of delays is minimal, and most closings are expected within the year.
Q:Is there potential to pay down additional debt with disposition activity completed in '25 beyond the debt maturing in 2026?
A:No, the excess capital will remain on the balance sheet as dry powder. The next debt maturity after 2026 is in 2028 with a 4.75% interest rate, so it is more beneficial to retain the debt and increase cash reserves.
Q:Review of Unclear Management Responses
A:Management avoided directly quantifying any top-line revenue disruption due to operator transitions, using vague language to describe the difficulty in assessing the impact. They also did not provide specific details on the variables that could delay disposition closings into 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AlerisLife community
GA expense
Medical Office
NOI basis
Office Life
Science portfolio
adjustment
average
balance sheet
capital spending
care level
cash flow
community operator
community transition
compensation expense
contract
cost
date
decline
fee incentive
feedback
increase SHOP
increase property
increase transition
industry
labor
momentum
objective
occupancy rate
price
pricing
property SHOP
review
service
termination
transaction
transition AlerisLife
wind
DHC Transcript
Diversified Healthcare Trust (DHC) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings report shows strong financial performance, with key metrics exceeding expectations, such as Normalized FFO and Adjusted EBITDAre. The company is experiencing NOI growth across segments and improving margins, which are positive indicators. The Q&A section provides additional insights into strategic investments and cost management, with management reaffirming guidance despite some uncertainties. The focus on ROI and reduced leverage adds to the positive sentiment. Overall, the financial health and strategic direction suggest a positive stock price movement.
Diversified Healthcare Trust (DHC) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reflects positive financial performance with significant improvements in NOI margins and leverage reduction. The strategic focus on operational performance and disciplined capital spending is promising. While the Q&A revealed some uncertainties, such as unclear timelines for reopening wings and acquisition strategies, the overall outlook remains optimistic. The positive elements, including strong occupancy and pricing momentum, outweigh the minor concerns, supporting a positive sentiment.
Diversified Healthcare Trust (DHC) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights positive financial performance with increased revenues, NOI, and occupancy across various segments. Despite temporary labor cost increases, the company maintains strong guidance and expects favorable transitions. The Q&A section reveals management's confidence in achieving targets and mitigating risks. The increase in SHOP NOI guidance and active disposition pipeline further support a positive outlook. However, the lack of specific details on potential revenue disruptions and disposition delays warrants caution. Overall, the sentiment leans towards positive due to strong financial metrics and optimistic guidance.
Diversified Healthcare Trust (DHC) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong financial performance with a 3% revenue increase and a significant 172% FFO growth, driven by operational improvements. Despite high interest rates on new financing, the company's asset sales and debt management strategies are positive. The Q&A reveals strategic asset dispositions and gradual occupancy growth, with no major negative trends. The reaffirmed guidance and improved debt metrics indicate stability. Overall, the sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
DHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
